The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

被引：0

作者：

Giai, Valentina ^{[1
]}

Stagno, Fabio ^{[2
]}

Rosso, Tiziana ^{[3
,4
]}

Castagnetti, Fausto ^{[5
,6
]}

Capodanno, Isabella ^{[7
]}

Bonifacio, Massimiliano ^{[8
,9
]}

Tiribelli, Mario ^{[10
]}

Galimberti, Sara ^{[11
]}

Bocchia, Monica ^{[12
]}

Gozzini, Antonella ^{[13
]}

Caocci, Giovanni ^{[14
]}

Patriarca, Andrea ^{[15
]}

Lanzarone, Giuseppe ^{[16
]}

Guella, Anna ^{[17
]}

Sora, Federica ^{[18
]}

Luciano, Luigiana ^{[19
]}

Scortechini, Anna Rita ^{[20
]}

di Renzo, Nicola ^{[21
]}

Musto, Pellegrino ^{[22
,23
]}

Pastore, Domenico ^{[24
]}

Maggi, Alessandro ^{[25
]}

Fava, Carmen ^{[26
,27
]}

Pavone, Vincenzo

Fozza, Claudio ^{[28
,29
]}

Spinosa, Giuseppina ^{[30
]}

Carella, Angelo Michele ^{[31
]}

Tarantini, Giuseppe ^{[32
]}

Martino, Bruno ^{[33
]}

Pizzuti, Michele ^{[34
]}

Mannarella, Clara ^{[35
]}

Saccona, Fabio

Rosti, Gianantonio ^{[36
]}

Pregno, Patrizia ^{[37
]}

Breccia, Massimo ^{[38
]}

Pane, Fabrizio ^{[3
,4
,39
]}

Ciccone, Giovannino ^{[40
,41
]}

Specchia, Giorgina ^{[42
]}

Saglio, Giuseppe ^{[43
]}

机构：

[1] Citta Salute Sci, Div Hematol, Turin, Italy

[2] AOU Policlin Rodolico San Marco, Div Hematol & Bone Marrow Transplant, Catania, Italy

[3] Citta Salute Sci, Clin Epidemiol Unit, Turin, Italy

[4] Citta Salute Sci, CPO Piemonte, Turin, Italy

[5] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[6] IRCCS Azienda Osped Univ Bologna, Hematol Unit, Bologna, Italy

[7] Azienda Unita Sanitaria Locale IRCCS, Hematol Unit, Reggio Emilia, Italy

[8] Azienda Osped Univ Integrata Verona, Dept Med, Verona, Italy

[9] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med, Hematol Area, Verona, Italy

[10] Univ Udine, Div Hematol & BMT, Dept Med Area, Udine, Italy

[11] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy

[12] Univ Siena, Azienda Osped Univ Senese, Hematol, Siena, Italy

[13] Univ Florence, Hematol, AOU Careggi, Florence, Italy

[14] Univ Cagliari, Businco Hosp, Dept Med Sci & Publ Hlth, Cagliari, Italy

[15] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[16] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[17] APSS Trento, Santa Chiara Hosp, Hematol Unit, Trento, Italy

[18] Univ Cattolica Sacro Cuore, Inst Hematol, Rome, Italy

[19] Univ Naples Federico II, Hematol Unit, Naples, Italy

[20] Polytech Univ Marche, Div Hematol, Dept Mol & Clin Sci, Ancona, Italy

[21] Osped V Fazzi, Haematol, Lecce, Italy

[22] Aldo Moro Univ, Sch Med, Dept Precis & Regenerat Med & Ionian Area, Haematl, Bari, Italy

[23] AOU Consorziale Policlin, Hematol & Stem Cell Transplantat Unit, Bari, Italy

[24] Osped A Perrino, Haematol, Brindisi, Italy

[25] Osped SG Moscati, Haematol, Taranto, Italy

[26] Mauriziano Hosp, Hematol, Turin, Italy

[27] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[28] Azienda C Panico, Hematol Unit, Tricase, Italy

[29] Univ Sassari, Azienda Osped Univ Sassari, Hematol Unit, Sassari, Italy

[30] Policlin Riuniti Osped Univ, Hematol Unit, Foggia, Italy

[31] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy

[32] Osped Mons Dimiccoli, Haematol, Barletta, Italy

[33] Grande Osped Metropolitano Bianchi Melacrino More, Hematol Unit, Reggio Di Calabria, Italy

[34] San Carlo Reg Hosp, Dept Oncohematol, Potenza, Italy

[35] Osped Madonna Grazie, Hematol Unit, Matera, Italy

[36] IRST IRCCS Dino Amadori, Med Oncol Unit, Meldola, FC, Italy

[37] Citta Salute Sci, Div Hematol, Turin, Italy

[38] Hematol Sapienza Univ, Dept Translat & Precis Med, Rome, Italy

[39] Azienda Osped Univ Federico II, Dipartimento Med Clin & Chirurgia, UOC Ematol & Trapianti Midollo, Naples, Italy

[40] AOU Citta Salute & Sci, SSD Epidemiol Clin & Valutativa, Turin, Italy

[41] CPO Piemonte, Turin, Italy

[42] Univ Bari, Hematol, Bari, Italy

[43] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182981

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 36 条

[31] Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
Pierga, J-Y
Tredant, O.
Chevrier, M.
Dubot, C.
Lorgis, V.
Romieu, G.
Goncalves, A.
Debled, M.
Levy, C.
Ferrero, J-M
Jouannaud, C.
Luporsi, E.
Mouret-Reynier, M-A
Dalenc, F.
Berger, F.
Lemonnier, J.
Proudhon, C.
Bidard, F-C
CANCER RESEARCH, 2017, 77
[32] First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.
Pronzato, Paolo
Mustacchi, Giorgio
Giordano, Monica
Garrone, Ornella
Del Mastro, Lucia
Natoli, Clara
Turletti, Anna
Romagnoli, Emanuela
Bologna, Alessandra
Mocerino, Carmela
Alu, Massimiliano
De Angelis, Claudia
Aversa, Caterina
Arpino, Grazia
Taverniti, Cristiana
Biganzoli, Laura
Meattini, Icro
Piezzo, Michela
Cazzaniga, Marina Elena
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Miles, D.
Puglisi, F.
Schneeweiss, A.
Ciruelos, E.
Peretz-Yablonski, T.
Moreno, K.
Restuccia, E.
Lasserre, S.
Bachelot, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S271 - S271
[34] Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial
Man, Xiaochu
Huang, Jie
Sun, Shujuan
Zhou, Dongdong
Zhang, Baoxuan
Fang, Shu
Zheng, Fangchao
Li, Chao
Wang, Xinzhao
Huang, Wei
Wang, Linlin
He, Qingqing
Fu, Hui
Zhang, Yan
Liu, Changrui
Dong, Lin
Zhao, Xianguang
Xu, Liang
Sun, Xiao
Fan, Bingjie
Song, Lihua
Zhou, Zhengbo
Yu, Jinming
Li, Huihui
CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (05):
[35] A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results
Papadimitrakopoulou, V.
Blumenschein, G. R., Jr.
Leighl, N. B.
Bennouna, J.
Soria, J. C.
Burris, H. A., III
Dimitrijevic, S.
Kunz, T.
Di Scala, L.
Johnson, B. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[36] Circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) predictive value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: Results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
Pierga, J-Y
Silveira, A.
Lorgis, V.
Tanguy, M-L
Tredan, O.
Dubot, C.
Jacot, W.
Goncalves, A.
Debled, M.
Levy, C.
Ferrero, J-M
Jouannaud, C.
Luporsi, E.
Mouret-Reynier, M-A
Dalenc, F.
Lemonnier, J.
Berger, F.
Proudon, C.
Bidard, F-C
CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 →